MiMedx Group, Inc. (NASDAQ:MDXG) Given Average Rating of “Buy” by Brokerages

MiMedx Group, Inc. (NASDAQ:MDXG) has been given an average recommendation of “Buy” by the five ratings firms that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $12.00.

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th.

MiMedx Group Price Performance

MiMedx Group stock opened at $8.79 on Friday. The stock has a market capitalization of $1.29 billion, a P/E ratio of 15.98 and a beta of 1.96. The company’s fifty day moving average price is $9.21 and its 200 day moving average price is $7.47. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, October 30th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. The business had revenue of $84.06 million during the quarter, compared to analysts’ expectations of $81.00 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. During the same quarter in the previous year, the company earned $0.05 earnings per share. As a group, equities research analysts anticipate that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. acquired a new stake in shares of MiMedx Group during the third quarter worth about $30,000. Point72 Asset Management L.P. acquired a new position in MiMedx Group during the second quarter worth $40,000. Point72 DIFC Ltd boosted its position in shares of MiMedx Group by 127.6% in the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after buying an additional 4,275 shares in the last quarter. Entropy Technologies LP acquired a new stake in shares of MiMedx Group in the third quarter valued at approximately $64,000. Finally, Orion Capital Management LLC increased its position in MiMedx Group by 46.3% during the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock worth $69,000 after purchasing an additional 3,700 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.